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Abstract 
Currently, development of subunit vaccine based on recombinant antigens or peptides 
has gradually become an important alternative option for traditional vaccine. However, 
induction of potent immune response with desired efficacy remains a major challenge. 
The nanoparticle-based antigen delivery system has been considered a potential carrier 
system to improve the efficacy of subunit vaccine. In the present study, we have 
designed an immune-stimulatory delivery system by conjugating three-armed PLGA to 
PEG via the peroxalate ester bond which is sensitive to hydrogen peroxide (H2O2), a 
major reactive oxygen species (ROS). Hyaluronic acid (HA), a ligand for CD44 
receptors was also modified onto the outer shell of the 3s-PLGA-PEG nanoparticles to 
promote immune cell uptake. For in vitro and in vivo immune response assessment, a 
model antigen ovalbumin (OVA) was enclosed within the core of the 3s-PLGA-PEG 
nanoparticles to form 3s-PLGA-PO-PEG/HA nanoparticles (PHO NPs). Our results 
showed that the PHO NPs enhanced dendritic cell maturation, antigen uptake and 
antigen presentation in vitro, likely due to enhanced lysosomal escape. In vivo 
experiments further revealed that the PHO nanovaccine robustly promoted OVA-
specific antibody production and T cell response accompanied by modest stimulation 
of memory T cells. In summary, the ROS-responsive PHO NPs with modified HA may 
be an effective vehicle antigen delivery system to promote antigen-induced immune 
response. 
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1 Introduction 
Designing and preparation of appropriate delivery systems for biomacromolecules such 
as genes, proteins, polypeptides remains a major challenge in the field of drug delivery 
system development1.The application of nanoparticles transferring system as vaccine 
carrier could potentially overcome limitations of subunit vaccines by increasing the 
antigen surface area, enhancing the stability of proteins, stabilizing the biological 
activity of antigens/proteins and augmenting the solubility of the antigen/protein 
complexes. Moreover, nanoparticles could prolong the systemic circulation time of 
antigens by processes such as encapsulation, which protects the active segments of 
antigens from endogenous enzyme degradation while promotes local accumulation. In 
addition, by employing nanoparticles as vaccine carriers, controlled and sustained 
release of antigens accompanied by other immune modulators can be achieved, which 
is essential to potent immune responses and lasting immune memory. In addition, 
studies have shown that nanoparticles can stimulate dendritic cell (DC) maturation and 
antigen presentation, both of which are crucial for the initiation of effective immune 
responses2, 3. Moreover, -it has been shown that nanoparticles can stimulate immune 
responses, and that their compatibility with the immune system are mainly dependent 
on surface chemical reactivity of the nanoparticles. Reducing the immune toxicity of 
nanoparticles could make them useful platforms for drug delivery4. 
Limited by their biological characteristics, biomacromolecules are easily degraded in 
vivo resulting in low bioavailability. As a result, for biomacromolecules delivery, 
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polymer nanocarriers have often been used5.However, while polymer nanocarriers 
improved bioavailability of the biomacromolecules, in vivo stability and toxicity have 
been reported with the use of liposomes and cationic polymers respectively. Instead, 
natural macromolecules have been shown to improve the distribution of nanoparticles 
in vivo with enhanced targeted delivery capability.  
Hyaluronic acid (HA) is a natural protein polysaccharide and often found in the 
extracellular matrix and connective tissues. It plays an important role in the 
maintenance of extracellular matrix structure and regulation of intracellular activity. It 
also functions as ligand to CD44 receptor, a transmembrane glycoprotein which is one 
of the most important receptors on the cell surface. HA and HA receptor CD44 as well 
as the HA binding protein (e.g., hyaluronan6, proteoglycans and glycoproteins such as 
aggrecan, versican, neurocan or brevican) regulate a variety of biological behaviors of 
cells including cell adhesion, migration, proliferation, differentiation and wound 
healing7. Studies have shown that CD44 is highly expressed on cells such as tumor cells, 
dendritic cells (DCs) and some epithelial cells8.The binding of CD44 and HA can 
trigger the combination of CD44 cytoplasmic domain and signal transduction 
molecules and then induce and activate intracellular signal transduction pathways such 
as Rho/Ras signal9. Given the high level of expression of CD44 on tumor and DC 
surface, HA has been widely used during the construction of nanoparticles for targeted 
drug/antigen delivery10. 
However, HA is easily degraded physiologically. When used alone as drug delivery 
system, it leads to reduced circulation time and drug leakage with decreased delivery 
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efficiency. Moreover, when inflammation occurs, certain enzymes can degrade HA 
derivatives, causing accidental drug release at the sites of inflammation11. One previous 
study has been reported that polyethylene glycol (PEG) modification of HA could 
prevent HA degradation and increase HA stability in vivo, likely due to effective 
inhibition of plasma protein, enzyme and other substances adhesion on the surface by 
PEGylation12. Thus, in the present study, we have designed a three-arm PLGA-PEG 
nanoparticle (3s-PLGA-PEG NPs) connected by peroxalate ester bonds as OVA antigen 
carrier, with HA modified on the external surface (3s-PLGA-PO-PEG/HA, PHO NPs). 
Since the peroxalate ester bonds are sensitive to ROS, which promotes in vivo immune 
responses and inflammation13, we expect that the PHO NPs would be able to target DCs 
by binding to the CD44 receptors while the ROS-responsiveness would enable targeted 
release of antigen for potent immune response induction. 
 
2 Experimental section 
2.1 Materials 
D,L-Lactide(DLA) and GA were supplied by Glaco Ltd (Beijing, China). PEG (Mn = 
4000 g/mol) wasbought from Guangfu Fine Chemical Research Institude (Tianjin, 
China). HA, Lipopolysaccharide(LPS), 3-(4,5-dimethyl-2-thiazolyl)-2,5-dipheny- l-2-
H-tetrazolium bromide(MTT), Phosphate Buffered Saline (PBS), Dimethyl sulfoxide 
(DMSO), Fluorescein isothiocyanate (FITC), 4’,6-diamidino-2-phenylindole (DAPI), 
Tween 20 were obtained by Solarbio (Beijing,China). Ovalbumin(OVA), Polyvinyl 
alcohol(PVA) (Mn=30000-70000), Carboxyfluorescein diacetate, succinimidyl ester 
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(CFSE), 2,7-Dichlorodi -hydrofluorescein diacetate (DCFH-DA) were obtained from 
Sigma-Aldrich (St. Louis, MO, USA). Cyanine7 NHS ester was obtained by Apexbio 
(USA). The Micro BCA™ Protein assay kit was supplied by Thermo Fisher Scientific 
Inc. (Rockford, IL USA). Lyso Tracker Red was purchased from Beyotime 
Biotechnology (Shanghai, China). Roswell Park Memorial Institute (RPMI) 1640 and 
fetalbovine serum (FBS) were purchased from Gibco (Grand Island, NY, USA). Anti-
mouse IgG Biotin, anti-mouse ELISA kits IL-6, TNF-alpha were purchased from 
eBioscience. Anti-mouse IgG1, IgG2a Biotin were obtained by BD bioscienses. 
Recombinant mouse GM-CSF and IL-4 were purchased from Peprotech (Rocky, Hill, 
USA). Fluorochrome-labeled anti-mouse monoclonal antibodies (CD3e, CD28，CD4, 
CD8a, CD11c, CD40, CD86, MHCI, MHCII, CD44, CD62L) were purchased from 
eBioscience (CA, USA). 
Female C57BL/6 mice(6-8-week-old) were purchased by National Institutes for Food 
and Drug Control (Beijing, China). All animal procedures were reviewed and ethically 
approved by Center of Tianjin Animal Experiment ethics committee and authority for 
animal protection (Approval No.:SYXK (Jin) 2011-0008). 
2.2 Synthesis of 3s-PLGA-PO-PEG 
The synthetic route of 3s-PLGA-PO-PEG was depicted as follow. The 3s-PLGA was 
firstly synthesized using lactide and glycolide by ring-opening polymerizationas 
previously reported14.The block copolymer was obtained when modified 3s-PLGA and 
PEG linked with oxalyl chloride by acylation reaction. Three-arm PLGA connected to 
PEG by peroxalate ester bond which breaks in the presence of H2O2.
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2.3 Preparation and characterization of NPs modified with HA 
A double emulsion (W1/O/W2) method was used to prepare 3s-PLGA-PO-PEG/HA NPs 
loaded OVA (PHO). Firstly, OVA aqueous solution was added in 2 mL dichloromethane 
which containing 50 mg 3s-PLGA-PEG(LA:GA=50:50) to form water-in-oil (W1/O) 
primary emulsion under a microtip probe sonicator (VCX-130-PB, Sonics & Material 
Inc., Connecticut, USA) at 30% amplitude for 10 min15. The first emulsion was then 
added in a secondary aqueous solution containing 1% (w/w) PVA with HA by 
ultrasonication at 30 % amplitude for another 10min to generate a W1/O/W2 double 
emulsion. The final preparation was stirred for 4 h and transferred into solid NPs until 
the dichloromethane completely removed. The HA-coated NPs were washed four times 
with distilled water by centrifugation at 23,000 rpm for 30 min before lyophilized and 
sterilized by gamma irradiation and stored at -20 °C in dry state and the supernatant 
was used to test loading capacity. The 3s-PLGA loaded OVA(P-O) NPs and 3s-PLGA-
PEG loaded OVA (PO) NPs were also prepared as control in the same way. NPs loaded 
OVA conjugated FITC (OVA-FITC) or OVA conjugated Cy7 NHS ester(OVA-Cy7) 
were prepared using the above describe method for the purpose of tracking. 
The average particle size, encapsulation and loading capacity and surface morphology 
were determined to evaluate the characteristics of NPs. The particle size, size 
distribution and surface charges of the NPs were determined by photon correlation 
spectroscopy (PCS)using Nano-ZS ZEN3600 (Malvern Instruments). Morphological 
test of NPs was measured and taken pictures by transmission electron microscopy 
(TEM, JEM-2100F, Japan). The NPs were suspended in water at 4°C over21 d and the 
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size was tested at different time to observe the size and distribution change of NPs. To 
determine the encapsulation efficiency (EE) and loading capacity (LC) of NPs, the 
amount of OVA in NPs and free OVA in supernatant were determined using BCA Assay 
Kit (Thermo, USA). The EE and LC calculated by the equations: EE = (total OVA − 
unbound OVA)/total OVA × 100%; LC = loaded OVA/total mass of nanovaccine × 
100%. The release kinetics experiment of NPs was carried out in phosphate buffer (PBS, 
pH 7.4) at 37 °C. 12 mg OVA-loaded NPs was suspended in PBS to release in shaking 
table at constant temperature (37 °C, 150 r/min). The release amounts of OVA from 
supernatant obtained by centrifugation (20000 r/min, 5 min) was measured at different 
time by BCA Assay Kit. 
2.4 The scavenging ability of H2O2 by NPs in vitro 
The scavenging ability of H2O2 by NPs was measured as follows. To 1 mL of H2O2 
solution (200 μM) was added 1 mg of polymer materials, P-O, PO, PHO NPs and free 
OVA and then was left in a shaker (150 r/min) at 37°C. The H2O2 concentration of 
supernatant was measured after 3 h incubation by Amplex Red Probe (Invitrogen, 
Carlsbad, CA). Human smooth muscle cells (SMC) were cultured with1 μg/mL LPS to 
induce intracellular ROS in a 24-well plate and then treated with NPs for 3 h. Then, 
ROS in cells was labeled by 10 μmol/L DCFH-DA. The fluorescence signal of ROS in 
cells was measured using a BD Accuri™ C6 flow cytometer (BD Biosciences, San Jose, 
CA). 
2.5 Dendritic cells viability assays 
To evaluate the potential cytotoxicity of NPs on cells, we performed a MTT assay of 
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cells treated with soluble OVA or NPs. DC 2.4 cells were cultured in RPMI1640 with 
10% FBS, 100 μg/mL penicillin, 100 μg/mL streptomycin under 5% CO2 at 37°C. They 
were seeded in96-well plates in 100 μL medium per well at a density of 5×104 cells/mL 
for 24 h and then cells were washed and incubated for another 24 h with 100 μL of 
medium-containing free OVA or NPs. Then, the NP-containing medium was removed. 
0.5mg/mL MTT solution in medium was added and kept for 4 h. At last, the supernatant 
was removed and 150 μL DMSO was added. Cells were covered with tinfoil and 
agitated on orbital shaker for 15 min. Absorbance was read at 490 nm with a reference 
filter of 630 nm using a microplate reader (Varioskan Flash 3001, Thermo, USA).  
2.6 Intracellular uptake of OVA by DC  
DC 2.4 cells were firstly cultured at 5×105 cells/well in a 24-well plate for 24 h and 
then treated with OVA-FITC (10 μg/mL) and nanoparticle-formulated OVA-FITC at 
37 °C for 4 h and then washed. The uptake percentage and mean fluorescence 
intensity(MFI) of OVA-FITC by DCs was measured by a BD Accuri™  C6 flow 
cytometer (BD Biosciences, San Jose, CA). 
2.7 Cellular uptake and localization of antigens in DC  
DC 2.4 cells were seeded in cover glass-bottom confocal dish at a density of 8×104 
cells/well overnight at 37 °C. Free OVA-FITC (10μg/mL) and OVA-FITC loaded NPs 
were placed in wells and incubated at 37 °C for 4 h. The cells were washed for three 
times and then were fixed with 4% paraformaldehyde. The 50nM LysoTraker Red 
DND-99 and DAPI was separately used to label endosomes and nucleus. The 
fluorescent images were recorded by a confocal laser scanning microscopy (CLSM 410; 
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Zeiss, Jena, Germany) 
2.8 Bone marrow dendritic cells (BMDCs) stimulation and maturation 
BMDCs which were isolated from C57BL/6J mice femurs and tibias. Erythrocytes were 
lysed by red cell lysing reagent. BMDCs were then cultured in complete RPMI1640 
medium containing 20 ng/mL GM-CSF and 10 ng/mL IL-4 for 6 d to obtain immature 
DCs16.The immature DCs were treated with free OVA (20 μg/mL) and OVA-loaded 
NPs for 24h. The levels of surface markers expression were observed by flow cytometry. 
The DCs were stained with anti-mouse CD11c, CD40, CD86 and CCR7 monoclonal 
antibodies for 30 min at 4 °C in the dark. Cells were washed twice and then analyzed 
by flow cytometry using a BD Accuri™ C6 flow cytometer (BD Biosciences, San Jose, 
CA). 
2.9 Antigen cross presentation in vitro 
In vitro antigen cross presentation by DCs was evaluated by B3Z T cell activation 
assay17.Immature BMDCs were harvested and pulsed with free OVA or OVA loaded 
NPs in a 24-well plate for 8 h at 37 °C. BMDCs were washed and then cocultured with 
B3Z T cells at a density of 5 ×105 cells/well which is the CD8+ T cell hybridoma 
presented by MHC class I molecules overnight. X-Gal substrate (1.5 mg/mL of X-Gal，
0.25% PBS-NP40) was added to the remaining cells and then incubated for 24 h. Finally, 
the positive signal was measured by a microplate reader (Thermo) at 405 nm. 
2.10 In vivo trafficking of cyanine 7-labeled NPs 
To investigate the effect of nanovaccines on lymphatic trafficking in vivo, OVA was 
labeled by near infrared (NIR) fluorescent Cyanine 7 dyes. C57BL/6 mice were 
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administrated by subcutaneous (s.c) injection at the tail base site and OVA-Cy7 and 
OVA-Cy7 NPs were then visualized at the injection site and the inguinal lymph nodes18. 
Cy7 fluorescent signals at different time (0, 6, 12, 24 h) was measured by Maestro 
imaging system (CRI, USA). Fluorescence quantitative change was measured by 
quantifying the fluorescent intensity. 
2.11 In vivo immunization, antibody production and in vitro T cell proliferation 
assay 
Six-to-eight-week-old female C57BL/6J mice (4 mice/group) were immunized with 
OVA or OVA-loaded NPs (20 μg OVA/mouse) by subcutaneous injection at a 2-week 
interval for three times. As for antibody production analysis, blood was collected 7 days 
after last immunization, OVA specific IgG, IgG1, IgG2a antibody in serum were 
determined by ELISA (eBioscience). 
Seven days post last immunization, splenocytes (1×106 cells/mL) were isolated and 
stimulated with OVA (20 μg/mL) in a 24-well plate for 72 h. The production of IL-6 in 
supernatants was measured by ELISA kit. To determine T lymphocytes proliferation, 
splenocytes were isolated and stained with 5 μmol/L CFSE (Sigma-Aldrich). After anti-
mouse CD3 and anti-mouse CD28 immobilized in a 24-well plate, the CFSE-dyed T 
cells (1×106 cells/mL) were incubated with 20 μg/mL soluble OVA for 72h. Finally, the 
cells were labeled with PE-anti-mouse CD4 or PE-anti-mouse CD8, and decreased 
CFSE intensity was determined to observe different T cell proliferation using flow 
cytometry. 
2.12 T cell activation response in vivo 
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Six-to-eight-week-old female C57BL/6J mice were immunized with OVA (20 μg/mL) 
or OVA loaded NPs twice every two weeks. Splenocytes (1×106 cells/mL) were isolated 
and cocultured with OVA (20 μg/mL) for 72 h at 37 °C. Cell surface markers FITC-
anti-mouse CD62L, APC-anti-mouse CD44, PE-anti-mouse CD4 or PE-anti-mouse 
CD8 were stained. Fluorescence populations were sorted using a BD Accuri™ C6 flow 
cytometer (BD Biosciences, San Jose, CA) to measure the amount of effectory memory 
T cells (CD44Hi CD62LLo) and central memory T cells (CD44Hi CD62LHi)19. 
2.13 Statistical analysis 
The quantitative data were presented as mean ± S.D. Statistical significance were 
analyzed using a student’s T-Test (*P<0.05; **P<0.01; ***P<0.001). 
 
3 Results and discussion 
3.1 Characterization of NPs 
NPs were prepared by a double emulsion (W1/O/W2) solvent evaporation method. 
Soluble OVA were added in PLGA or PLGA-PEG organic phase to form W1/O primary 
emulsion. The emulsion was then emulsified in PVA with HA to multiple emulsion 
(W1/O/W2). Due to the binding affinity of HA to CD44 receptors, we expect that the 
PHO NPs would be readily taken up by antigen-presenting cells(APCs), such as DCs, 
following recognition of CD44 receptor on APCs cell surface. Since uptake of foreign 
particles would activate the NADPH-oxidase which catalyzes the glycolytic reactions 
and results in H2O2 generation, the ROS-responsive NPs would then degenerate in an 
H2O2-rich environment within DCs due to breakage of the peroxalate ester bonds, 
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leading to release of antigen within the NPs. 
 
Table 1. Characteristics of OVA-loaded P-O, PO, PHO. Data are shown as the 
mean±SD (n=3). 
NPs Size(nm) PDI Zeta potential(mV) EE LC 
P-O 219.3 ± 0.82 0.144 ± 0.016 -19.9 ± 0.3 15.2 ± 0.8 3.6 ± 0.2 
PO 200.0 ± 2.43 0.270 ± 0.003 -22.0 ± 1.4 85.0 ± 11.1 12.5 ± 0.9 
PHO 225.0 ± 1.29 0.097 ± 0.034 -7.27 ± 0.4 94.4 ± 2.1 15.4 ± 0.3 
 
 
Fig. 1 The physical properties of NPs in vitro. (A) PHO size distribution. (B) TEM 
image of PHO. (C) The change of PHO particle size and PDI for 21 d was measured to 
observe the stability of particles. (D) The release kinetics curve of P-O, PO, PHO in 
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PBS (0.01 M, pH 7.4) for 21d. Data are mean ± SD (n=3). 
 
Thus, OVA loaded 3s-PLGA-PO-PEG/HA (PHO) NPs, 3s-PLGA (P-O) NPs and 3s-
PLGA-PO-PEG (PO) NPs were prepared. The average diameter of PHO NPs was 
225.0±1.29 nm and polydispersity index (PDI) was 0.097±0.034. The size distribution 
of PHO NPs was presented in Fig. 1A. The surface charge of PHO NPs was -7.27±0.4 
mV (Table 1). The results of TEM and Dynamic Light Scattering showed that all groups 
of NPs exhibited dispersed spherical shape of similar size (Fig. 1B).  
The protein capsulation efficiency (EE) and loading capacity (LC) were listed in Table 
1. We found that PEGylation increased OVA loading likely due to the hydrophilicity of 
PEG. In addition, HA modification also increased viscosity of NPs and protein adhesion. 
The stability of the NPs was then investigated. Our results observed no evident 
morphological changes of all groups of NPs for 21 days at 4 ℃，indicating suitable 
stability of the NPs (Fig. 1C).  
It has been demonstrated that PEG fragments not only increase the stability of NPs, but 
also reduce proteolysis, both of which result in increased circulation time and improved 
efficacy20.Since HA is a member of the mucopolysaccharide family with high viscosity 
that may attenuate protein release, we have also examined the protein releasing ability 
of the NPs (Fig. 1D). We observed sustained OVA release from all OVA-loaded NPs in 
PBS (pH 7.4) for 21 days. A burst release of more than 20% was detected during the 
first day for P-O and PO, followed by a slower and continued release for 20 days. In 
contrast, OVA were released from the PHO NPs in a slower manner compared to the P-
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O and PO groups, mainly due to the viscosity of the HA coatings.  
Given that smaller particles (20-200 nm) tend to accumulate within the LN-resident 
DCs and other monocytic APCs21,our NPs could potentially be effective nanovaccine 
delivery vehicles considering their narrow size distribution, high encapsulation 
efficiency, stability and sustained antigen-releasing property. 
3.2 Hydrogen peroxide responsiveness of NPs in vitro 
It has been known that the peroxyl oxalic easter bonds, which connect the PLGA and 
PEG segments of the 3s-PLGA-PO-PEG NPs, are sensitive to H2O2. In the presence 
ofH2O2, breakage of the PO bonds would lead to degeneration of the NPs. To assess the 
responsiveness and the scavenging H2O2 property of the NPs by the amplex red 
hydrogen/peroxidase assay22.As shown in Fig. 2A, the concentrations of remaining 
H2O2 detected from PO or PHO NPs were fewer in comparison to P-O NPs and PEG 
solution. To further examine the H2O2 clearance action of the ROS-responsive NPs, 
human fibroblast NIH 3T3 cells were treated with NPs. ROS was labeled with DCFH-
DA probe and quantified using flow cytometry. We observed reduced H2O2 levels from 
cells treated with soluble OVA, P-O, PO and PHO NPs compared to control cells (Fig. 
2B). Cells treated with PHO NPs showed the most substantial decrease of ROS than 
cells treated with OVA or P-O, demonstrating better ROS scavenging ability of the PHO 
NPs.  
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Fig. 2 H2O2 scavenging of NPs in vitro. (A) Scavenging activity of polymer materials 
and NPs determined by the Amplex Red Assay. (B) Scavenging of H2O2 by NPs in cells 
determined by a DCFH-DA probe. (C) Cytotoxicity of NPs for DC2.4 cells after 24 h 
determined by the MTT assay. The values shown are mean ± SD (n=3). *P < 0.05, **P 
< 0.01 and ***P < 0.001 to control. 
 
3.3 In vitro stability and toxicity of NPs 
To determine in vitro stability and toxicity of the NPs, cell viability was assessed using 
a dendritic cell line (DC 2.4). Cell viability was performed using the MTT assay after 
cells were treated with a series of NPs ranging from 12.5 μg/mL to 400 μg/mL. Cell 
viability was calculated as follows: cell viability% = (sample OD - blank OD) / 
(negative control OD – blank OD) ×100%. As shown in Fig. 2C, DC 2.4 cells exposed 
to all groups of NPs exhibited robust viability. The results demonstrated that NPs 
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composed of PLGA, PEG, HA exhibited excellent in vitro biological compatibility and 
are suitable as vaccine delivery vehicles. 
3.4 NPs enhanced antigen uptake, DC maturation and cross-presentation 
Antigens are initially processed by APCs, such as DCs and macrophages. These cells 
then regulate subsequent immune responses via antigen presentation of processed 
antigens to T or B cells. The potency of immune responses, as a result, is dependent on 
efficacy of antigen presentation of APCs following antigen uptake. Since HA bind to 
CD44 receptors on surface of cells such as DCs, the PHO NPs would enable targeted 
antigen delivery and uptake, which would be expected to increase efficiency of antigen 
presentation. We therefore have investigated the effect of all groups of NPs on antigen 
uptake, DC maturation and cross-presentation using the model antigen OVA uptake and 
localization of OVA-FITC was examined by confocal fluorescent microscopy (Fig. 3A) 
in DC2.4 cells. The images showed that soluble OVA-FITC and P-O NP groups was 
co-localized with lysosomes (shown in red) and the green fluorescence which 
corresponds to OVA-FITC was rather faint, indicating low level of free OVA uptake. 
Compared with soluble OVA, we observed more intense green fluorescence signal that 
indicates elevated intracellular OVA in cells treated with PO and PHO NPs. In cells 
treated with PO and PHO NPs, majority of OVA uptake was detected in the cytosolic 
space separated from lysosomes, demonstrative of “lysosomal escape” of the antigen 
and possible cross-presentation downstream. 
The exact amounts of OVA-FITC uptake by DCs treated with different groups of NPs 
were quantified by measuring the mean fluorescence intensity (MFI) of FITC via flow 
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cytometry. As shown in Fig. 3B, an over 10-fold increase of OVA-FITC uptake was 
observed in DCs co-cultured with PHO NPs in comparison to OVA control group. 
Similar pattern was also observed in the MFI of OVA-FITC uptake (Fig. 3C). These 
results indicate that HA could enhance antigen recognition and internalization by DCs, 
possibly via its binding to CD44 receptors. In addition, we also observed increased 
OVA-FITC uptake from cells treated with PO NPs in comparison to P-O, which suggest 
PEGylation also improve antigen uptake.  Moreover, since antigens uptake promotes 
a host of intracellular ROS production in cells. Our ROS-responsive NPs would further 
target to immune cells following phagocytosis of OVA. 
 
 
Fig. 3 Cellular uptake and endosomal release of NPs by DC2.4 cells. (A) Confocal 
microscope images of DC2.4 cells after incubated with soluble OVA-FITC and OVA-
FITC NPs for 3 h. The scale bar shows 20 µm. (B) The percentage of OVA-FITC uptake 
was determined by flow cytometry. (C) The intracellular MFI of DC 2.4 cells cocultured 
with soluble OVA-FITC and OVA-FITC NPs for 3 h was detected by flow cytometry. 
Bars shown are mean ± SD (n=3). *P < 0.05, **P < 0.01 and ***P < 0.001 to OVA 
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groups. 
 
 
Fig. 4 Cellular uptake and endosomal release of NPs by BMDC cells. Confocal 
microscope images of BMDC cells after incubated with soluble OVA-FITC and OVA-
FITC NPs for 3 h. The scale bar shows 20 µm.  
 
Dendritic cells play an essential role in antigen presentation and vaccine induced 
adaptive immunity. The recognition and antigen uptake by immature DCs is the first 
process during induction of immune responses. Following antigens uptake, DCs would 
undergo and become ready for subsequent processing of the antigens and presentation 
to T cells, a stage often referred to as maturation and characterized by up-regulation of 
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costimulatory molecules (such as CD40 and CD86) on maturated DC cell surface. Since 
DC maturation is critical to T cell and immune response activation, we have further 
investigated the effect of NPs on DC maturation in vitro using bone marrow derived 
DCs (BMDCs). Thus, immature BMDCs were harvested on day 7 and exposed to NPs 
for 24h. Both PO and PHO NPs enhanced the expression of CD40 and CD86 (Fig. 5A, 
B), indicating their capability of promoting DC maturation.  
Antigen cross-presentation is another step following antigen uptake and DC maturation, 
during which DCs present the processed antigens to CD4+ or CD8+ T cells through the 
MHC class II or MHC class I pathways, respectively. To measure the effects of NPs on 
antigen presentation, BMDCs were pulsed with free OVA or NP-formulated OVA for 
24 h, and co-cultured with OVA-responsive B3Z T cells hybridoma overnight. Indeed, 
the LacZ B3Z T cells are sensitive to OVA class I epitope SIINFEKL that is known to 
be presented by the MHC class I H-2Kb on DCs and are able to generate β-galactosidase 
upon antigen recognition, concentrations of β-galactosidase were quantified from all 
tested groups23. As shown in Fig.5C,P-O NPs significantly enhanced the value of OD 
405 by 2folds compared to free OVA, indicating OVA-specific CD8+T cell activation. 
PO and PHO NPs also induced significantly elevated CD8+T cell activation than free 
OVA. It has been known that endogenous antigens are often presented via the MHC 
class I pathway, while exogenous antigens are presented via the MHC class II 
pathway24.Since our results showed up-regulation of CD8+ T cell activation following 
exposure to NP-delivered OVA, it could be said that NPs promoted antigen cross 
presentation possibly due to enhanced DC phagocytosis, antigen release and lysosomal 
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escape that had been observed with the ROS-responsive NPs. Cytokine release by 
mature DCs is also important for the induction of local immune responses. We have 
also measured cytokine productions in supernatants of BMDCs that had been co-
cultured with NP-delivered OVAs. As shown in Fig. 5D, E, BMDCs secreted 
significantly more IL-6 and TNF-α following NPs stimulation compared to free OVA, 
consistent with a pro-inflammatory role of the NP-delivered OVAs.  
Our results indicate that NPs promoted antigen uptake, DC maturation and cross-
presentation, accompanied by pro-inflammatory cytokine production compared to free 
OVA. However, no significant differences could be detected among different 
composition of the NPs, which could mean that the PLGA NPs themselves were a 
potent adjuvant. Indeed, previous studies have reported adjuvant property of PLGA, 
consistent with our results25. 
 
 
Fig. 5 BMDCs maturation and cytokine production induced by free OVA or NPs 
cocultured for 24 h in vitro. (A, B) The expression of CD40 and CD86 on BMDCs was 
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determined using flow cytometry. (C) MHC I antigen presentation by BMDCs to B3Z 
cells to observe CD8+T cell activation in vitro. (D, E) The secretion of IL-6 and TNF-
α from BMDCs with different NPs. The values were mean ± SD (n=3).*P < 0.05, **P 
< 0.01 and ***P < 0.001 to soluble OVA. 
 
3.6 Nanovaccine enhances antigen in vivo trafficking  
As an important immune organ, lymph nodes will uptake antigen by DCs or 
macrophages to activate immune response. Antigens are expected to migrate to the 
draining lymph nodes and NP in vivo trafficking has been used as an indicator to 
monitor vaccine delivery. It has been reported that smaller particles were more often 
found in lymph nodes while larger particles were more efficiently phagocytosed by 
DCs26.As a result, considering that the NPs used in the present study range less than 
200 nm, we expect that they would be readily transferred to lymph node following 
administration. To assess the effect of NPs on migration properties, fluorescently 
labeled OVA (OVA-Cy7) and NPs-delivered OVA-Cy7 were injected by 
subcutaneously at the tail base site and in vivo trafficking of OVA-Cy7 was monitored 
by examining the fluorescence signal of Cy7 using a small animal in vivo imaging 
system. 
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Fig. 6 Antigen persistence at injection sites and transport into the right inguinal draining 
lymph node to determine in vivo tracking of OVA-Cy7 and OVA-Cy7 NPs. (A) 
Fluorescence images of different NPs in mice. (B) The total signal intensity of antigen 
in the right draining lymph node was calculated. 
 
As shown in Fig. 6A, significantly strong fluorescence signals were observed in the 
inguinal draining lymph node at 6 h from mice received free OVA, and the signals 
increased at 12 h followed by a rapid decrease 24 h after injection. In contrast, the 
fluorescence signals of mice received P-O, PO, PHO NPs migrated slowly and the 
residence time in lymph nodes was prolonged compared to free OVA. The fluorescence 
signals detected in lymph nodes of all NPs group became stronger 12 h after initial 
administration. For mice received PHO NPs in particular, robust fluorescence signal 
was detected at 24 h (Fig. 6B), which could be due to increased DC targeting property 
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of the NPs as a result of HA modification. We also monitored the fluorescence signals 
for more than 1 week with attenuated fluorescence intensity detectable as time extended. 
Nevertheless, we found that administration of NPs would result in slow accumulation 
and retention of OVA in the LNs compared to soluble OVA (Fig. S1). 
3.7 Nanovaccine enhanced in vivo T cell activation and antibody production 
Six-week old female C57BL/6J mice were immunized with OVA or OVA-loaded NPs 
(20 μg OVA/mouse) as detailed in the Methods section. Splenocytes were then isolated 
7 days after the last immunization and labeled appropriately as previously reported for 
T-cell proliferation study27. We found that mice immunized with PO and PHO NPs had 
elevated numbers of spleen CD8+ T cells than other groups (Fig. 7A, B). Up-regulation 
of CD4+ T cell number was also observed in mice treated with PO NPs (Fig. 7A). As 
shown in Fig. 7C, D, increased percentages of both CD4+CFSElowand CD8+CFSElow T 
cells were observed in all NP groups compared to free OVA. Since T cell proliferation 
is a key indication of immune activation, these results implicate a stimulatory role of 
NPs on both CD4+ and CD8+ T cells proliferation and immune activation. However, 
administration of PHO nanoparticles did not increase T-cell proliferation or activation 
in vitro, which could be due to the lack of memory T/B cell and circulating cytokines 
signaling system in a simplified in vitro environment. The aim of vaccine design is to 
induce adaptive immune response, i.e. cellular or humoral immunity. In general, antigen 
presenting cells (APC), including DCs, mononuclear / macrophages, are part of the 
innate immune system and are the first line of defense during pathogen invasion. The 
antigens can be identified and transported locally by the DCs from the infected 
26 
 
peripheral tissues or transferred systemically to the lymph nodes for further processing. 
DCs stimulate the response of T cells to antigens, usually by the pattern recognition 
receptor (PRR) to identify the immunogenic components. The commonly 
acknowledged PRRs are Toll like receptors and mannose receptors. The Toll like 
receptors recognize a variety of bacteria and viruses. Following PRR identification on 
DC surface, the pathogen / antigen is usually taken in by the DC through endocytosis / 
phagocytosis. When the antigen enters APCs such as DCs, it is then presented by MHC- 
I or MHC- II molecules. Exogenous particles, viruses, or pathogens are usually 
processed into small molecular antigens and then packed into the MHC- II molecules. 
The MHC- II presentation pathway then initiates the activation of auxiliary T cells, 
which further stimulates the production of antibodies or cellular immunity. On the other 
hand, the MHC- I presentation pathway is often activated through endogenous antigens 
within the cytoplasm of DCs. Together, the MHC- I and II presentation is known as 
cross presentation. Ultimately, the antigen presentation process triggers downstream 
signaling protein (cytokine) activation and induce adaptive immunity of the auxiliary T 
cells (Th cells). Taken all the above into consideration, the PLGA–based nanovaccine 
carriers are likely able to to induce cellular immune responses and Th1 immune 
responses in vivo as observed in previous and our present study3, 28.29 
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Fig. 7 Effect of NPs on promoting T cell proliferation and MHC I and II antigen 
presentation pathway. (A, B) CD4+ and CD8+ T cells were obtained and restimulated 
with OVA from immunized mouse splenocytes isolated 7days after last immunization. 
(C, D) The percentage of CFSE low proliferated CD4+ and CD8+ T cells labeled with 
CFSE, PE-anti-mouse CD4 or PE-anti-mouse CD8 was determined with decreased 
CFSE intensity using flow cytometry. The values are mean ± SD (n=3). *P < 0.05, **P 
< 0.01 and ***P < 0.001 to OVA group. 
 
To determine humoral immune response in vivo, C57BL/6J mice were immunized with 
OVA or OVA-loaded NPs, and anti-OVA IgG antibodies were measured 7 days post last 
immunization. As shown in Fig. 8, P-O and PO NPs induced anti-OVA specific IgG by 
10-30 folds, meanwhile PHO NPs increased IgG production by 50 folds. We also 
measured anti-OVA IgG1 and IgG2a levels. The PHO NPs enhanced OVA-specific 
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IgG1 and IgG2a production more than other NPs and free OVA. It is known that in mice, 
Th1 T cell activation will often produce IgG2a antibody whilst Th2 T cell activation 
would likely induce IgG1 antibody generation30.As a result, since elevation of both 
IgG2a and IgG1 antibodies was observed, the PHO NPs would likely promote both Th1 
and Th2 cell immune response in vivo. In addition, elevated IL-6 production was also 
observed in splenocytes extracted from mice treated with PHO NPs, confirming a 
potent role of the PHO NPs in promoting immune cells proliferation, differentiation 
and CTL response induction. 
 
 
Fig. 8 Antigen-specific antibody production in the C57BL/6 mice immunized with OVA 
or OVA-loaded nanoparticles. (A-C) OVA specific IgG, IgG1, IgG2a titers in serum 
were measured using ELISA. (D) The secretion of IL-6 in supernatants was measured 
from splenocytes isolated after immunization and re-stimulated with soluble OVA for 
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72h. The values are mean ± SD (n=3). *P < 0.05, **P < 0.01 and ***P < 0.001 to soluble 
OVA. 
 
3.8 Nanovaccines enhanced memory T cell proliferation in vivo 
Memory T cell responses were measured by lymph node homing receptors. According 
to the difference of expression of lymph node homing receptors, memory T cells are 
divided into effector memory T cells (CD44Hi CD62LLo) for rapid effector function and 
central memory T cells (CD44HiCD62LHi) for potent proliferation and lymph node 
homing properties31, 32. As shown in Fig. S2, the PHO NPs improved central memory 
T cells proliferation in both CD4+ T cells compared to other NPs. However, there was 
no significant difference from all groups in effector memory T cells, which may due to 
the effective cells gathering in central lymphoid organ. 
 
4 Conclusions 
In the present study, we have designed a ROS-triggered 3s-PLGA-PO-PEG 
nanoparticle-based antigen delivery system with HA modification that targets the CD44 
receptors on DC surface (PHO NPs). We found that the PHO NPs enhanced dendritic 
cell maturation, antigen uptake, lysosomal escape and antigen presentation in vitro. 
PHO NPs also robustly promoted OVA-specific antibody production while stimulated 
antigen-induced both CD4+and CD8+ T cell responses as well as memory T cells (Fig.9). 
In summary, the ROS-triggered nanoparticle-based antigen delivery system could 
enhance vaccine-induced cellular and humoral immune responses and may be a 
promising candidate as a novel vaccine.  
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Fig. 9 The design of nano vaccine and possible cellular mechanisms. The preparation 
of nano vaccine: 3s-PLGA-PO-PEG/HA nanoparticles loaded OVA (PHO) were 
formulated by a double emulsion (W1/O/W2) solvent evaporation method and modified 
with HA. The PHO was taken up by APCs following recognition by CD44 receptor on 
APCs. The nanoparticles would be splitting in H2O2 environment in cells. The 
exogenous NPs loaded antigen were processed by endo/lysosomes following presented 
to CD4+ T cells via MHC II pathway. The NPs also could escape lysosome phagocytosis 
and would be dissembled in H2O2 environment. The antigen would be presented to 
CD8+ T cells via MHC I pathway. 
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